Latest News

Transcend Therapeutics Presents New Data from the Open-Label Portion of the IMPACT-1 Study and Further Data Supporting the Neuroplasticity Mechanism of TSND-201

TSND-201 (Methylone) for the Treatment of PTSD: Improvements across each CAPS-5 Cluster and Anxiety Symptoms from the Open-Label Portion of the IMPACT-1 Study

TSND-201 (Methylone): A Rapid-Acting Neuroplastogen that Stimulates Neurite Outgrowth

Transcend Therapeutics Presents New Data At ASCP Demonstrating Improvements In Functioning And Sleep-Related Symptoms in PTSD Patients Treated with TSND-201 (Methylone)

TSND-201 for the Treatment for PTSD: Functional and Global Improvements from the Open-Label Portion of the IMPACT-1 Study (T36)

TSND-201 for the Treatment for PTSD: Improvement in Sleep-Related Outcomes from the Open-label Portion of the IMPACT-1 Study (W45)

TSND-201, a rapid-acting treatment for PTSD and other Central Nervous System (CNS) disorders (T89)

Transcend Therapeutics announces publication of new preclinical data demonstrating TSND-201 (methylone) is a rapid-acting neuroplastogen with fewer off-target effects than MDMA

Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA

Fierce Biotech: Psychiatry biotech hopes to Transcend PTSD rivals with new data

TSND-201 (methylone) for PTSD: Initial Results from Open-Label Study (IMPACT-1)

Transcend Therapeutics Announces Positive Open-Label Data from IMPACT-1